News

Enlarge image

BusinessGermanyNetherlands

Bayer partners with KeyGene

24.04.2013 - Bayer Crop Science has entered a multi-year R&D partnership with Keygene to improve traits in crops.

The German and the Dutch company announced that the scope of their first research programme is wheat, potentially to be followed by projects in oilseed rape, rice and cotton. In the collaboration, Bayer will access KeyGene’s KeySeeQ® discovery pipeline. The platform technology will be used to identify genes associated with novel traits such as drought tolerance. The genes will be then improved by KeyGene using its automated high throughput targeted mutagenesis tool KeyPoint®. Bayer will be responsible for global market introduction of the resulting new wheat varieties.

“Bayer has the goal to offer farmers tailor-made wheat varieties with improved yield and other agronomically-important traits including drought tolerance and nitrogen use efficiency,” said David Nicholson, Global R&D Head at Bayer CropScience. However, it's not an easy task to create new varieties in wheat due to its polyploidy and the involvement of many genes in such complex traits such as drought tolerance.   However, improving the tolerance of wheat varieties to cope with drought and other environmental stress factors is important across the world.

Wheat is one of the most important staple crops for humans: the worldwide consumption was 704 million tons in 2011. It is expected that by 2030 farmers will face an increase of 40% in the world-wide demand for wheat. Therefore, new varieties need to provide farmers with important agricultural innovations which help them to sustainably increase yield and profitability.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/bayer-partners-with-keygene.html

R&DUKIreland

12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.

CommercialisationEU

10.02.2016 In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)5.10 SEK20.00%
  • KARO BIO (S)29.30 SEK19.59%
  • PLETHORA (UK)2.75 GBP4.96%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • PAION (D)1.08 EUR-13.60%

TOP

  • VERONA PHARMA (UK)3.40 GBP30.8%
  • IXICO (UK)35.75 GBP21.2%
  • SAREUM HOLDINGS (UK)0.28 GBP12.0%

FLOP

  • PAION (D)1.08 EUR-56.3%
  • BIONOR PHARMA (N)0.79 NOK-51.8%
  • PROTHENA PLC (IE)30.12 USD-41.6%

TOP

  • KARO BIO (S)29.30 SEK3755.3%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • NICOX (F)6.45 EUR224.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.70 SEK-86.1%
  • BIOTEST (D)13.81 EUR-85.2%
  • EVOCUTIS (UK)0.08 GBP-69.2%

No liability assumed, Date: 11.02.2016